Primary vitreoretinal lymphoma: a diagnostic and management challenge - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Blood Année : 2021

Primary vitreoretinal lymphoma: a diagnostic and management challenge

Le lymphome vitréo-rétinien : un challenge diagnostique et thérapeutique

Résumé

Primary vitreoretinal lymphoma (PVRL) is a rare form of primary central nervous system (CNS) lymphoma (PCNSL) arising in the intraocular compartment without brain involvement. Despite its apparent indolent clinical course, PVRL can cause permanent vision loss and CNS relapse, the major cause of death in patients with PVRL. The pathophysiology of PVRL is unknown. As in PCNSL, the transformation of the tumor cells likely originates outside the CNS, before the cells migrate to the eye and proliferate within an immune-permissive microenvironment. PVRL exhibits a biased immunoglobulin repertoire, suggesting underlying antigen selection. The diagnosis remains challenging, requiring close coordination between ophthalmologists and cytologists. Because of their rarity and fragility in the vitreous, lymphoma cells cannot always be identified. Interleukin levels, molecular biology, and imaging are used in combination with clinical ophthalmological examination to support the diagnosis of PVRL. Multi-institutional prospective studies are urgently needed to validate the equivocal conclusions regarding treatments drawn from heterogeneous retrospective or small cohort studies. Intravitreal injection of methotrexate or rituximab or local radiotherapy is effective at clearing tumor cells within the eyes but does not prevent CNS relapse. Systemic treatment based on high-dose methotrexate chemotherapy, with or without local treatment, might reduce this risk. At relapse, intensive consolidation chemotherapy followed by stem cell transplantation can be considered. Single-agent ibrutinib, lenalidomide, and temozolomide treatments are effective in patients with relapsed PVRL and should be tested as first-line treatments. Therapeutic response assessment based on clinical examination is improved by measuring cytokine levels but still needs to be refined.
Fichier principal
Vignette du fichier
PVRL_Blood_Manuscript soumis_bis.pdf (4.35 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03559353 , version 1 (20-02-2022)

Identifiants

Citer

Carole Soussain, Denis Malaise, Nathalie Cassoux. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood, 2021, 138 (17), pp.1519-1534. ⟨10.1182/blood.2020008235⟩. ⟨hal-03559353⟩
569 Consultations
435 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More